Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

26.21
+0.22500.87%
Volume:5K
Turnover:137.87K
Market Cap:1.45B
PE:-21.60
High:26.30
Open:26.30
Low:26.10
Close:25.98
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:0.77
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2134
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:2.99
PE(LYR):-0.33

Loading ...

Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy Benchmark

TIPRANKS
·
Jul 15

Aktis Oncology is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 14

J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS)

TIPRANKS
·
Jul 14

Aktis Oncology price target raised to $33 from $30 at JPMorgan

TIPRANKS
·
Jul 14

Top Brass at Aktis Oncology Cash In With Major Stock Disposals

TIPRANKS
·
Jul 11

Aktis Oncology CMO Akos Czibere Disposes of Common Shares Worth $1.29 Million

Reuters
·
Jul 10

U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation

Reuters
·
Jun 16

Aktis Oncology initiated with a Strong Buy at Raymond James

TIPRANKS
·
Jun 16

Aktis Oncology posts investor presentation on miniprotein radioconjugate platform, lead Nectin-4 and B7-H3 programs

Reuters
·
Jun 11

Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 03

Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright

TIPRANKS
·
Jun 03

Aktis Oncology, Inc. : H.c. Wainwright Raises Target Price to $35 From $33

THOMSON REUTERS
·
Jun 02

Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update

TIPRANKS
·
May 28

Aktis Oncology CEO to present at Jefferies Global Healthcare Conference

Reuters
·
May 28

Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity

TIPRANKS
·
May 27

Aktis Oncology posts presentation on AKY-2519 clinical imaging, dosimetry data for B7-H3-targeted radioconjugate

Reuters
·
May 27

Top Premarket Gainers

MT Newswires Live
·
May 22

Aktis Oncology (AKTS) Valuation Check After Recent Share Price Weakness And Lower Price To Book Ratio

Simply Wall St.
·
May 22

Aktis Oncology reports first-in-human AKY-2519 imaging data showing robust tumor uptake

Reuters
·
May 22

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for Aky-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients With B7-H3 Expressing Tumors

THOMSON REUTERS
·
May 22